Abstract
Microcystic adnexal carcinoma (MAC) and sebaceous carcinoma (SC) are rare adnexal neoplasms. MAC most commonly presents as a poorly defined, firm, skin-colored papule, nodule, or plaque on the head and neck. Although locally destructive, MAC does not typically metastasize. Rates of misdiagnosis are high, due to incomplete, superficial sampling. Resection techniques with meticulous margin control, including Mohs micrographic surgery (MMS), are recommended in the management of MAC.
Sebaceous carcinoma, originating from holocrine sebocytes, is often found on the head and neck and is among the most common eyelid neoplasms. SC commonly presents as a firm, subcutaneous nodule with a yellow hue. SC may masquerade as other neoplastic and inflammatory entities, delaying diagnosis. Patients with SC must be screened for Muir-Torre syndrome, a hereditary cancer syndrome. Treatment for SC is surgical. SC has metastatic potential, most commonly to draining lymph node basins. Radiation and chemotherapy play a role in the management of metastatic disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Goldstein DJ, Barr RJ, Santa Cruz DJ. Microcystic adnexal carcinoma: a distinct clinicopathologic entity. Cancer. 1982;50(3):566–72.
Pujol RM, LeBoit PE, Su WP. Microcystic adnexal carcinoma with extensive sebaceous differentiation. Am J Dermatopathol. 1997;19(4):358–62.
Nickoloff BJ, Fleischmann HE, Carmel J, Wood CC, Roth RJ. Microcystic adnexal carcinoma. Immunohistologic observations suggesting dual (pilar and eccrine) differentiation. Arch Dermatol. 1986;122(3):290–4.
Boos MD, Elenitsas R, Seykora J, Lehrer MS, Miller CJ, Sobanko J. Benign subclinical syringomatous proliferations adjacent to a microcystic adnexal carcinoma: a tumor mimic with significant patient implications. Am J Dermatopathol. 2014;36(2):174–8.
Cardoso JC, Calonje E. Malignant sweat gland tumours: an update. Histopathology. 2015;67(5):589–606.
Chiller K, Passaro D, Scheuller M, Singer M, McCalmont T, Grekin RC. Microcystic adnexal carcinoma: forty-eight cases, their treatment, and their outcome. Arch Dermatol. 2000;136(11):1355–9.
Yu JB, Blitzblau RC, Patel SC, Decker RH, Wilson LD. Surveillance, Epidemiology, and End Results (SEER) database analysis of microcystic adnexal carcinoma (sclerosing sweat duct carcinoma) of the skin. Am J Clin Oncol. 2010;33(2):125–7.
Diamantis SA, Marks VJ. Mohs micrographic surgery in the treatment of microcystic adnexal carcinoma. Dermatol Clin. 2011;29(2):185–90. viii.
Fu T, Clark FL, Lorenz HP, Bruckner AL. Congenital microcystic adnexal carcinoma. Arch Dermatol. 2011;147(2):256–7.
Peterson CM, Ratz JL, Sangueza OP. Microcystic adnexal carcinoma: first reported case in an African American man. J Am Acad Dermatol. 2001;45(2):283–5.
Nadiminti H, Nadiminti U, Washington C. Microcystic adnexal carcinoma in African-Americans. Dermatol Surg. 2007;33(11):1384–7.
Ohtsuka H, Nagamatsu S. Microcystic adnexal carcinoma: review of 51 Japanese patients. Dermatology. 2002;204(3):190–3.
Chen J, Yang S, Liao T, Deng W, Li W. Microcystic adnexal carcinoma in a non-Caucasian patient: a case report and review of the literature. Oncol Lett. 2016;11(4):2471–4.
Tolkachjov SN, Schmitt AR, Muzic JG, Weaver AL, Baum CL. Incidence and clinical features of rare cutaneous malignancies in Olmsted County, Minnesota, 2000 to 2010. Dermatol Surg. 2017;43(1):116–24.
Wick MR, Cooper PH, Swanson PE, Kaye VN, Sun TT. Microcystic adnexal carcinoma. An immunohistochemical comparison with other cutaneous appendage tumors. Arch Dermatol. 1990;126(2):189–94.
Avraham JB, Villines D, Maker VK, August C, Maker AV. Survival after resection of cutaneous adnexal carcinomas with eccrine differentiation: risk factors and trends in outcomes. J Surg Oncol. 2013;108(1):57–62.
LeBoit PE, Sexton M. Microcystic adnexal carcinoma of the skin. A reappraisal of the differentiation and differential diagnosis of an underrecognized neoplasm. J Am Acad Dermatol. 1993;29(4):609–18.
Snow S, Madjar DD, Hardy S, Bentz M, Lucarelli MJ, Bechard R, et al. Microcystic adnexal carcinoma: report of 13 cases and review of the literature. Dermatol Surg. 2001;27(4):401–8.
Carroll P, Goldstein GD, Brown CW. Metastatic microcystic adnexal carcinoma in an immunocompromised patient. Dermatol Surg. 2000;26(6):531–4.
Smith KJ, Williams J, Corbett D, Skelton H. Microcystic adnexal carcinoma: an immunohistochemical study including markers of proliferation and apoptosis. Am J Surg Pathol. 2001;25(4):464–71.
Wohlfahrt C, Ternesten A, Sahlin P, Islam Q, Stenman G. Cytogenetic and fluorescence in situ hybridization analyses of a microcystic adnexal carcinoma with del(6)(q23q25). Cancer Genet Cytogenet. 1997;98(2):106–10.
Kishi M, Nakamura M, Nishimine M, Ishida E, Shimada K, Kirita T, et al. Loss of heterozygosity on chromosome 6q correlates with decreased thrombospondin-2 expression in human salivary gland carcinomas. Cancer Sci. 2003;94(6):530–5.
Dupré A, Carrère S, Bonafé JL, Christol B, Lassère J, Touron P. Eruptive generalized syringomas, milium and atrophoderma vermiculata. Nicolau and Balus' syndrome (author's transl). Dermatologica. 1981;162(4):281–6.
Ranasinghe AR, Batchelor J, Ha T. Nicolau Balus syndrome with microcystic adnexal carcinoma. J Am Acad Dermatol. 2013;68(4):AB56.
Schaller J, Rytina E, Rütten A, Hendricks C, Ha T, Requena L. Sweat duct proliferation associated with aggregates of elastic tissue and atrophodermia vermiculata: a simulator of microcystic adnexal carcinoma. Report of two cases. J Cutan Pathol. 2010;37(9):1002–9.
Page RN, Hanggi MC, King R, Googe PB. Multiple microcystic adnexal carcinomas. Cutis. 2007;79(4):299–303.
Leibovitch I, Huilgol SC, Selva D, Lun K, Richards S, Paver R. Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52(2):295–300.
Connolly KL, Nehal KS, Disa JJ. Evidence-based medicine: cutaneous facial malignancies: nonmelanoma skin cancer. Plast Reconstr Surg. 2017;139(1):181e–90e.
Friedman PM, Friedman RH, Jiang SB, Nouri K, Amonette R, Robins P. Microcystic adnexal carcinoma: collaborative series review and update. J Am Acad Dermatol. 1999;41(2 Pt 1):225–31.
Yugueros P, Kane WJ, Goellner JR. Sweat gland carcinoma: a clinicopathologic analysis of an expanded series in a single institution. Plast Reconstr Surg. 1998;102(3):705–10.
Obaidat NA, Alsaad KO, Ghazarian D. Skin adnexal neoplasms--part 2: an approach to tumours of cutaneous sweat glands. J Clin Pathol. 2007;60(2):145–59.
Sellheyer K, Nelson P, Kutzner H, Patel RM. The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers. J Cutan Pathol. 2013;40(4):363–70.
Fu JM, McCalmont T, Yu SS. Adenosquamous carcinoma of the skin: a case series. Arch Dermatol. 2009;145(10):1152–8.
Frouin E, Vignon-Pennamen MD, Balme B, Cavelier-Balloy B, Zimmermann U, Ortonne N, et al. Anatomoclinical study of 30 cases of sclerosing sweat duct carcinomas (microcystic adnexal carcinoma, syringomatous carcinoma and squamoid eccrine ductal carcinoma). J Eur Acad Dermatol Venereol. 2015;29(10):1978–94.
Sebastien TS, Nelson BR, Lowe L, Baker S, Johnson TM. Microcystic adnexal carcinoma. J Am Acad Dermatol. 1993;29(5 Pt 2):840–5.
Crowson AN, Magro CM, Mihm MC. Malignant adnexal neoplasms. Mod Pathol. 2006;19(Suppl 2):S93–S126.
Urso C, Bondi R, Paglierani M, Salvadori A, Anichini C, Giannini A. Carcinomas of sweat glands: report of 60 cases. Arch Pathol Lab Med. 2001;125(4):498–505.
Merritt BG, Snow SN, Longley BJ. Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: differentiation by immunohistochemistry and determining the need for Mohs micrographic surgery. Cutis. 2010;85(5):254–8.
Costache M, Bresch M, Böer A. Desmoplastic trichoepithelioma versus morphoeic basal cell carcinoma: a critical reappraisal of histomorphological and immunohistochemical criteria for differentiation. Histopathology. 2008;52(7):865–76.
Shinohara R, Ansai S, Ogita A, Matsuda H, Saeki H, Tanaka M. Dermoscopic findings of microcystic adnexal carcinoma. Eur J Dermatol. 2015;25(5):516–8.
Hoang MP, Dresser KA, Kapur P, High WA, Mahalingam M. Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Mod Pathol. 2008;21(2):178–85.
Nagatsuka H, Rivera RS, Gunduz M, Siar CH, Tamamura R, Mizukawa N, et al. Microcystic adnexal carcinoma with mandibular bone marrow involvement: a case report with immunohistochemistry. Am J Dermatopathol. 2006;28(6):518–22.
Krahl D, Sellheyer K. Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma. J Cutan Pathol. 2007;34(10):782–7.
Abesamis-Cubillan E, El-Shabrawi-Caelen L, PE LB. Merked cells and sclerosing epithelial neoplasms. Am J Dermatopathol. 2000;22(4):311–5.
Patrizi A, Neri I, Marzaduri S, Varotti E, Passarini B. Syringoma: a review of twenty-nine cases. Acta Derm Venereol. 1998;78(6):460–2.
Salasche SJ, Amonette RA. Morpheaform basal-cell epitheliomas. A study of subclinical extensions in a series of 51 cases. J Dermatol Surg Oncol. 1981;7(5):387–94.
Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344(13):975–83.
Wang Q, Ghimire D, Wang J, Luo S, Li Z, Wang H, et al. Desmoplastic trichoepithelioma: a clinicopathological study of three cases and a review of the literature. Oncol Lett. 2015;10(4):2468–76.
Popadić M. Dermoscopy of aggressive basal cell carcinomas. Indian J Dermatol Venereol Leprol. 2015;81(6):608–10.
Tawfik AM, Kreft A, Wagner W, Vogl TJ. MRI of a microcystic adnexal carcinoma of the skin mimicking a fibrous tumour: case report and literature review. Br J Radiol. 2011;84(1002):e114–7.
Gomez-Maestra MJ, España-Gregori E, Aviñó-Martinez JA, Mancheño-Franch N, Peña S. Brainstem and cavernous sinus metastases arising from a microcystic adnexal carcinoma of the eyebrow by perineural spreading. Can J Ophthalmol. 2009;44(3):e17–8.
Beltramini GA, Baj A, Moneghini L, Poli T, Combi VA, Giannì AB. Microcystic adnexal carcinoma of the centrofacial region: a case report. Acta Otorhinolaryngol Ital. 2010;30(4):213.
Cooper PH, Mills SE, Leonard DD, Santa Cruz DJ, Headington JT, Barr RJ, et al. Sclerosing sweat duct (syringomatous) carcinoma. Am J Surg Pathol. 1985;9(6):422–33.
Abbate M, Zeitouni NC, Seyler M, Hicks W, Loree T, Cheney RT. Clinical course, risk factors, and treatment of microcystic adnexal carcinoma: a short series report. Dermatol Surg. 2003;29(10):1035–8.
Palamaras I, McKenna JD, Robson A, Barlow RJ. Microcystic adnexal carcinoma: a case series treated with mohs micrographic surgery and identification of patients in whom paraffin sections may be preferable. Dermatol Surg. 2010;36(4):446–52.
Lopez M, Cole EL. Microcystic adnexal carcinoma: reconstruction of a large centrofacial defect. Plast Reconstr Surg Glob Open. 2014;2(11):e254.
Eisen DB, Zloty D. Microcystic adnexal carcinoma involving a large portion of the face: when is surgery not reasonable? Dermatol Surg. 2005;31(11 Pt 1):1472–7. discussion 8.
Rotter N, Wagner H, Fuchshuber S, Issing WJ. Cervical metastases of microcystic adnexal carcinoma in an otherwise healthy woman. Eur Arch Otorhinolaryngol. 2003;260(5):254–7.
Green M, Mitchum M, Marquart J, Bowden LP, Bingham J. Microcystic adnexal carcinoma in the axilla of an 18-year-old woman. Pediatr Dermatol. 2014;31(6):e145–8.
Ban M, Sugie S, Kamiya H, Kitajima Y. Microcystic adnexal carcinoma with lymph node metastasis. Dermatology. 2003;207(4):395–7.
Gulmen S, Pullon PA. Sweat gland carcinoma of the lips. Oral Surg Oral Med Oral Pathol. 1976;41(5):643–9.
Stein JM, Ormsby A, Esclamado R, Bailin P. The effect of radiation therapy on microcystic adnexal carcinoma: a case report. Head Neck. 2003;25(3):251–4.
Baxi S, Deb S, Weedon D, Baumann K, Poulsen M. Microcystic adnexal carcinoma of the skin: the role of adjuvant radiotherapy. J Med Imaging Radiat Oncol. 2010;54(5):477–82.
Yuh WT, Engelken JD, Whitaker DC, Dolan KD. Bone marrow invasion of microcystic adnexal carcinoma. Ann Otol Rhinol Laryngol. 1991;100(7):601–3.
Shields JA, Demirci H, Marr BP, Eagle RC, Shields CL. Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol. 2005;50(2):103–22.
Tripathi R, Chen Z, Li L, Bordeaux JS. Incidence and survival of sebaceous carcinoma in the United States. J Am Acad Dermatol. 2016;75(6):1210–5.
Doxanas MT, Green WR. Sebaceous gland carcinoma. Review of 40 cases. Arch Ophthalmol. 1984;102(2):245–9.
Kyllo RL, Brady KL, Hurst EA. Sebaceous carcinoma: review of the literature. Dermatol Surg. 2015;41(1):1–15.
Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol. 2005;6(12):980–7.
Dores GM, Curtis RE, Toro JR, Devesa SS, Fraumeni JF. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome. Cancer. 2008;113(12):3372–81.
Nelson BR, Hamlet KR, Gillard M, Railan D, Johnson TM. Sebaceous carcinoma. J Am Acad Dermatol. 1995;33(1):1–15. quiz 6-8.
Natarajan K, Rai R, Pillai SB. Extra ocular sebaceous carcinoma: a rare case report. Indian Dermatol Online J. 2011;2(2):91–3.
Brady KL, Hurst EA. Sebaceous carcinoma treated with Mohs micrographic surgery. Dermatol Surg. 2017;43(2):281–6.
Slutsky JB, Jones EC. Periocular cutaneous malignancies: a review of the literature. Dermatol Surg. 2012;38(4):552–69.
Pereira PR, Odashiro AN, Rodrigues-Reyes AA, Correa ZM, de Souza Filho JP, Burnier MN. Histopathological review of sebaceous carcinoma of the eyelid. J Cutan Pathol. 2005;32(7):496–501.
Reifler DM, Hornblass A. Squamous cell carcinoma of the eyelid. Surv Ophthalmol. 1986;30(6):349–65.
Nemoto Y, Arita R, Mizota A, Sasajima Y. Differentiation between chalazion and sebaceous carcinoma by noninvasive meibography. Clin Ophthalmol. 2014;8:1869–75.
Coates D, Bowling J, Haskett M. Dermoscopic features of extraocular sebaceous carcinoma. Australas J Dermatol. 2011;52(3):212–3.
Rao NA, Hidayat AA, McLean IW, Zimmerman LE. Sebaceous carcinomas of the ocular adnexa: a clinicopathologic study of 104 cases, with five-year follow-up data. Hum Pathol. 1982;13(2):113–22.
Ni C, Searl SS, Kuo PK, Chu FR, Chong CS, Albert DM. Sebaceous cell carcinomas of the ocular adnexa. Int Ophthalmol Clin. 1982;22(1):23–61.
Yin VT, Merritt HA, Sniegowski M, Esmaeli B. Eyelid and ocular surface carcinoma: diagnosis and management. Clin Dermatol. 2015;33(2):159–69.
Wali UK, Al-Mujaini A. Sebaceous gland carcinoma of the eyelid. Oman J Ophthalmol. 2010;3(3):117–21.
Cook BE, Bartley GB. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota. Ophthalmology. 1999;106(4):746–50.
Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer. 2009;115(1):158–65.
Blake PW, Bradford PT, Devesa SS, Toro JR. Cutaneous appendageal carcinoma incidence and survival patterns in the United States: a population-based study. Arch Dermatol. 2010;146(6):625–32.
Wolfe JT, Yeatts RP, Wick MR, Campbell RJ, Waller RR. Sebaceous carcinoma of the eyelid. Errors in clinical and pathologic diagnosis. Am J Surg Pathol. 1984;8(8):597–606.
Dowd MB, Kumar RJ, Sharma R, Murali R. Diagnosis and management of sebaceous carcinoma: an Australian experience. ANZ J Surg. 2008;78(3):158–63.
Kass LG, Hornblass A. Sebaceous carcinoma of the ocular adnexa. Surv Ophthalmol. 1989;33(6):477–90.
Sung D, Kaltreider SA, Gonzalez-Fernandez F. Early onset sebaceous carcinoma. Diagn Pathol. 2011;6:81.
Kivelä T, Asko-Seljavaara S, Pihkala U, Hovi L, Heikkonen J. Sebaceous carcinoma of the eyelid associated with retinoblastoma. Ophthalmology. 2001;108(6):1124–8.
Abdi U, Tyagi N, Maheshwari V, Gogi R, Tyagi SP. Tumours of eyelid: a clinicopathologic study. J Indian Med Assoc. 1996;94(11):405. -9, 16, 18.
Kiyosaki K, Nakada C, Hijiya N, Tsukamoto Y, Matsuura K, Nakatsuka K, et al. Analysis of p53 mutations and the expression of p53 and p21WAF1/CIP1 protein in 15 cases of sebaceous carcinoma of the eyelid. Invest Ophthalmol Vis Sci. 2010;51(1):7–11.
Hussain RM, Matthews JL, Dubovy SR, Thompson JM, Wang G. UV-independent p53 mutations in sebaceous carcinoma of the eyelid. Ophthal Plast Reconstr Surg. 2014;30(5):392–5.
Gonzalez-Fernandez F, Kaltreider SA, Patnaik BD, Retief JD, Bao Y, Newman S, et al. Sebaceous carcinoma. Tumor progression through mutational inactivation of p53. Ophthalmology. 1998;105(3):497–506.
Shalin SC, Sakharpe A, Lyle S, Lev D, Calonje E, Lazar AJ. p53 staining correlates with tumor type and location in sebaceous neoplasms. Am J Dermatopathol. 2012;34(2):129–35. quiz 36-8.
Hayashi N, Furihata M, Ohtsuki Y, Ueno H. Search for accumulation of p53 protein and detection of human papillomavirus genomes in sebaceous gland carcinoma of the eyelid. Virchows Arch. 1994;424(5):503–9.
Cho KJ, Khang SK, Koh JS, Chung JH, Lee SS. Sebaceous carcinoma of the eyelids: frequent expression of c-erbB-2 oncoprotein. J Korean Med Sci. 2000;15(5):545–50.
Stagner AM, Afrogheh AH, Jakobiec FA, Iacob CE, Grossniklaus HE, Deshpande V, et al. p16 expression is not a surrogate marker for high-risk human papillomavirus infection in periocular sebaceous carcinoma. Am J Ophthalmol. 2016;170:168–75.
Kwon MJ, Shin HS, Nam ES, Cho SJ, Lee MJ, Lee S, et al. Comparison of HER2 gene amplification and KRAS alteration in eyelid sebaceous carcinomas with that in other eyelid tumors. Pathol Res Pract. 2015;211(5):349–55.
Liau JY, Liao SL, Hsiao CH, Lin MC, Chang HC, Kuo KT. Hypermethylation of the CDKN2A gene promoter is a frequent epigenetic change in periocular sebaceous carcinoma and is associated with younger patient age. Hum Pathol. 2014;45(3):533–9.
Landis MN, Davis CL, Bellus GA, Wolverton SE. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy. J Am Acad Dermatol. 2011;65(5):1054–8.e1.
Hoss E, Nelson SA, Sharma A. Sebaceous carcinoma in solid organ transplant recipients. Int J Dermatol. 2017;56:746.
Yen MT, Tse DT. Sebaceous cell carcinoma of the eyelid and the human immunodeficiency virus. Ophthal Plast Reconstr Surg. 2000;16(3):206–10.
Rumelt S, Hogan NR, Rubin PA, Jakobiec FA. Four-eyelid sebaceous cell carcinoma following irradiation. Arch Ophthalmol. 1998;116(12):1670–2.
Hood IC, Qizilbash AH, Salama SS, Young JE, Archibald SD. Sebaceous carcinoma of the face following irradiation. Am J Dermatopathol. 1986;8(6):505–8.
Schlernitzauer DA, Font RL. Sebaceous gland carcinoma of the eyelid. Arch Ophthalmol. 1976;94(9):1523–5.
Izumi M, Tang X, Chiu CS, Nagai T, Matsubayashi J, Iwaya K, et al. Ten cases of sebaceous carcinoma arising in nevus sebaceus. J Dermatol. 2008;35(11):704–11.
Wenzel CT, Halperin EC, Fisher SR. Second malignant neoplasms of the head and neck in survivors of retinoblastoma. Ear Nose Throat J. 2001;80(2):106, 9–12.
Lemos LB, Santa Cruz DJ, Baba N. Sebaceous carcinoma of the eyelid following radiation therapy. Am J Surg Pathol. 1978;2(3):305–11.
Howrey RP, Lipham WJ, Schultz WH, Buckley EG, Dutton JJ, Klintworth GK, et al. Sebaceous gland carcinoma: a subtle second malignancy following radiation therapy in patients with bilateral retinoblastoma. Cancer. 1998;83(4):767–71.
John AM, Schwartz RA. Muir-Torre syndrome (MTS): an update and approach to diagnosis and management. J Am Acad Dermatol. 2016;74(3):558–66.
Mahalingam M. MSH6, past and present and Muir-Torre syndrome-connecting the dots. Am J Dermatopathol. 2017;39(4):239–49.
Schwartz RA, Torre DP. The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol. 1995;33(1):90–104.
Jessup CJ, Redston M, Tilton E, Reimann JD. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome. Hum Pathol. 2016;49:1–9.
Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res. 2012;18(6):1506–12.
Cohen PR, Kohn SR, Kurzrock R. Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med. 1991;90(5):606–13.
Lazar AJ, Lyle S, Calonje E. Sebaceous neoplasia and Torre-Muir syndrome. Curr Diagn Pathol. 2007;13(4):301–19.
Bhaijee F, Brown AS. Muir-Torre syndrome. Arch Pathol Lab Med. 2014;138(12):1685–9.
Grob A, Feser C, Grekin S. Muir-torre syndrome:a case associated with an infrequent gene mutation. J Clin Aesthet Dermatol. 2016;9(1):56–9.
Singh RS, Grayson W, Redston M, Diwan AH, Warneke CL, McKee PH, et al. Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. Am J Surg Pathol. 2008;32(6):936–42.
Zürcher M, Hintschich CR, Garner A, Bunce C, Collin JR. Sebaceous carcinoma of the eyelid: a clinicopathological study. Br J Ophthalmol. 1998;82(9):1049–55.
Demirci H, Nelson CC, Shields CL, Eagle RC, Shields JA. Eyelid sebaceous carcinoma associated with Muir-Torre syndrome in two cases. Ophthal Plast Reconstr Surg. 2007;23(1):77–9.
Wick MR, Goellner JR, Wolfe JT, Su WP. Adnexal carcinomas of the skin. II. Extraocular sebaceous carcinomas. Cancer. 1985;56(5):1163–72.
Hou JL, Killian JM, Baum CL, Otley CC, Roenigk RK, Arpey CJ, et al. Characteristics of sebaceous carcinoma and early outcomes of treatment using Mohs micrographic surgery versus wide local excision: an update of the Mayo Clinic experience over the past 2 decades. Dermatol Surg. 2014;40(3):241–6.
Cook BE, Bartley GB. Treatment options and future prospects for the management of eyelid malignancies: an evidence-based update. Ophthalmology. 2001;108(11):2088–98; quiz 99–100, 121.
Shields JA, Demirci H, Marr BP, Eagle RC, Shields CL. Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology. 2004;111(12):2151–7.
Wang JK, Liao SL, Jou JR, Lai PC, Kao SC, Hou PK, et al. Malignant eyelid tumours in Taiwan. Eye (Lond). 2003;17(2):216–20.
Husain A, Blumenschein G, Esmaeli B. Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol. 2008;47(3):276–9.
Muqit MM, Roberts F, Lee WR, Kemp E. Improved survival rates in sebaceous carcinoma of the eyelid. Eye (Lond). 2004;18(1):49–53.
Boniuk M, Zimmerman LE. Sebaceous carcinoma of the eyelid, eyebrow, caruncle, and orbit. Trans Am Acad Ophthalmol Otolaryngol. 1968;72(4):619–42.
Sawyer AR, McGoldrick RB, Mackey S, Powell B, Pohl M. Should extraocular sebaceous carcinoma be investigated using sentinel node biopsy? Dermatol Surg. 2009;35(4):704–8.
Rulon DB, Helwig EB. Cutaneous sebaceous neoplasms. Cancer. 1974;33(1):82–102.
Chang AY, Miller CJ, Elenitsas R, Newman JG, Sobanko JF. Management considerations in extraocular sebaceous carcinoma. Dermatol Surg. 2016;42(Suppl 1):S57–65.
Shalin SC, Lyle S, Calonje E, Lazar AJ. Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications. Histopathology. 2010;56(1):133–47.
Font R. Eyelids and lacrimal drainage system. In: Spencer WH, editor. Ophthalmic pathology: an atlas and textbook. 3rd ed. Philadelphia: WB Saunders; 1986. p. 2169–214.
Pfeiffer ML, Yin VT, Myers J, Esmaeli B. Regional nodal recurrence of sebaceous carcinoma of the caruncle 11 years after primary tumor resection. JAMA Ophthalmol. 2013;131(8):1091–2.
Kohler S, Rouse RV, Smoller BR. The differential diagnosis of pagetoid cells in the epidermis. Mod Pathol. 1998;11(1):79–92.
Sramek B, Lisle A, Loy T. Immunohistochemistry in ocular carcinomas. J Cutan Pathol. 2008;35(7):641–6.
Beer TW, Shepherd P, Theaker JM. Ber EP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinomas of the skin. Histopathology. 2000;37(3):218–23.
Ansai SI. Topics in histopathology of sweat gland and sebaceous neoplasms. J Dermatol. 2017;44(3):315–26.
Rajan Kd A, Burris C, Iliff N, Grant M, Eshleman JR, Eberhart CG. DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma. Am J Ophthalmol. 2014;157(3):640–7.e1–2.
Buitrago W, Joseph AK. Sebaceous carcinoma: the great masquerader: emerging concepts in diagnosis and treatment. Dermatol Ther. 2008;21(6):459–66.
Esmaeli B, Nasser QJ, Cruz H, Fellman M, Warneke CL, Ivan D. American joint committee on cancer T category for eyelid sebaceous carcinoma correlates with nodal metastasis and survival. Ophthalmology. 2012;119(5):1078–82.
American Joint Committee on Cancer. New York, NY: Springer; 2010.
Reina RS, Parry E. Aggressive extraocular sebaceous carcinoma in a 52-year-old man. Dermatol Surg. 2006;32(10):1283–6.
Orcurto A, Gay BE, Sozzi WJ, Gilliet M, Leyvraz S. Long-term remission of an aggressive sebaceous carcinoma following chemotherapy. Case Rep Dermatol. 2014;6(1):80–4.
Herceg D, Kusacić-Kuna S, Dotlić S, Petrović R, Bracić I, Horvatić Herceg G, et al. F-18 FDG PET evaluation of a rapidly growing extraocular sebaceous carcinoma. Clin Nucl Med. 2009;34(11):798–801.
Baek CH, Chung MK, Jeong HS, Son YI, Choi J, Kim YD, et al. The clinical usefulness of (18)F-FDG PET/CT for the evaluation of lymph node metastasis in periorbital malignancies. Korean J Radiol. 2009;10(1):1–7.
Ginsberg J. Present status of meibomian gland carcinoma. Arch Ophthalmol. 1965;73:271–7.
Erovic BM, Goldstein DP, Kim D, Al Habeeb A, Waldron J, Ghazarian D, et al. Sebaceous gland carcinoma of the head and neck: the Princess Margaret Hospital experience. Head Neck. 2013;35(3):316–20.
Bailet JW, Zimmerman MC, Arnstein DP, Wollman JS, Mickel RA. Sebaceous carcinoma of the head and neck. Case report and literature review. Arch Otolaryngol Head Neck Surg. 1992;118(11):1245–9.
Tryggvason G, Bayon R, Pagedar NA. Epidemiology of sebaceous carcinoma of the head and neck: implications for lymph node management. Head Neck. 2012;34(12):1765–8.
Ho VH, Ross MI, Prieto VG, Khaleeq A, Kim S, Esmaeli B. Sentinel lymph node biopsy for sebaceous cell carcinoma and melanoma of the ocular adnexa. Arch Otolaryngol Head Neck Surg. 2007;133(8):820–6.
Nijhawan N, Ross MI, Diba R, Ahmadi MA, Esmaeli B. Experience with sentinel lymph node biopsy for eyelid and conjunctival malignancies at a cancer center. Ophthal Plast Reconstr Surg. 2004;20(4):291–5.
Savar A, Oellers P, Myers J, Prieto VG, Torres-Cabala C, Frank SJ, et al. Positive sentinel node in sebaceous carcinoma of the eyelid. Ophthal Plast Reconstr Surg. 2011;27(1):e4–6.
Harrington CR, Egbert BM, Swetter SM. Extraocular sebaceous carcinoma in a patient with Muir-Torre syndrome. Dermatol Surg. 2004;30(5):817–9.
Pfeiffer ML, Savar A, Esmaeli B. Sentinel lymph node biopsy for eyelid and conjunctival tumors: what have we learned in the past decade? Ophthal Plast Reconstr Surg. 2013;29(1):57–62.
Spencer JM, Nossa R, Tse DT, Sequeira M. Sebaceous carcinoma of the eyelid treated with Mohs micrographic surgery. J Am Acad Dermatol. 2001;44(6):1004–9.
Grigoryan KV, Leithauser L, Gloster HM. Aggressive extraocular sebaceous carcinoma recurring after mohs micrographic surgery. Case Rep Oncol Med. 2015;2015:534176.
Callahan EF, Appert DL, Roenigk RK, Bartley GB. Sebaceous carcinoma of the eyelid: a review of 14 cases. Dermatol Surg. 2004;30(8):1164–8.
Dogru M, Matsuo H, Inoue M, Okubo K, Yamamoto M. Management of eyelid sebaceous carcinomas. Ophthalmologica. 1997;211(1):40–3.
Snow SN, Larson PO, Lucarelli MJ, Lemke BN, Madjar DD. Sebaceous carcinoma of the eyelids treated by mohs micrographic surgery: report of nine cases with review of the literature. Dermatol Surg. 2002;28(7):623–31.
Cavanagh HD, Green WR, Goldberg HK. Multicentric sebaceous adenocarcinoma of the meibomian gland. Am J Ophthalmol. 1974;77(3):326–32.
Nunery WR, Welsh MG, McCord CD. Recurrence of sebaceous carcinoma of the eyelid after radiation therapy. Am J Ophthalmol. 1983;96(1):10–5.
Hendley RL, Rieser JC, Cavanagh HD, Bodner BI, Waring GO. Primary radiation therapy for meibomian gland carcinoma. Am J Ophthalmol. 1979;87(2):206–9.
Hata M, Koike I, Omura M, Maegawa J, Ogino I, Inoue T. Noninvasive and curative radiation therapy for sebaceous carcinoma of the eyelid. Int J Radiat Oncol Biol Phys. 2012;82(2):605–11.
Yen MT, Tse DT, Wu X, Wolfson AH. Radiation therapy for local control of eyelid sebaceous cell carcinoma: report of two cases and review of the literature. Ophthal Plast Reconstr Surg. 2000;16(3):211–5.
Pardo FS, Wang CC, Albert D, Stracher MA. Sebaceous carcinoma of the ocular adnexa: radiotherapeutic management. Int J Radiat Oncol Biol Phys. 1989;17(3):643–7.
Jung YH, Woo IS, Kim MY, Han CW, Rha EY. Palliative 5-fluorouracil and cisplatin chemotherapy in recurrent metastatic sebaceous carcinoma: case report and literature review. Asia Pac J Clin Oncol. 2016;12(1):e189–93.
Murthy R, Honavar SG, Burman S, Vemuganti GK, Naik MN, Reddy VA. Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis. Ophthal Plast Reconstr Surg. 2005;21(4):307–9.
Priyadarshini O, Biswas G, Biswas S, Padhi R, Rath S. Neoadjuvant chemotherapy in recurrent sebaceous carcinoma of eyelid with orbital invasion and regional lymphadenopathy. Ophthal Plast Reconstr Surg. 2010;26(5):366–8.
Paschal BR, Bagley CS. Sebaceous land carcinoma of the eyelid: complete response to sequential combination chemotherapy. N C Med J. 1985;46(9):473–4.
el Nakadi B, Nouwynck C, Salhadin A. Combined therapeutic approach for extraorbital sebaceous carcinoma in a Torre's syndrome. Eur J Surg Oncol. 1995;21(3):321–2.
De Leo A, Innocenzi D, Onesti MG, Potenza C, Toscani M, Scuderi N. Extraocular sebaceous carcinoma in Muir Torre Syndrome with unfavorable prognosis. Cancer Chemother Pharmacol. 2006;58(6):842–4.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Massey, P.R., Soldano, A.C., Fox, M.C. (2018). Adnexal Carcinoma: Microcystic Adnexal Carcinoma and Sebaceous Carcinoma. In: Hanlon, A. (eds) A Practical Guide to Skin Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-74903-7_10
Download citation
DOI: https://doi.org/10.1007/978-3-319-74903-7_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-74901-3
Online ISBN: 978-3-319-74903-7
eBook Packages: MedicineMedicine (R0)